imvaria was founded in 2019 by a team of physician-engineers from Stanford and Google, seeking to empower clinicians and improve patient outcomes through the development and application of modern computer science techniques to complex and serious diseases. The company's Digital Biomarker Platform enables non-invasive diagnostic and therapeutic patient stratification via data science and machine learning.
imvaria's lead work is assigned FDA's Breakthrough Device Designation.
imvaria's lead work is assigned FDA's Breakthrough Device Designation.
Location: United States
Employees: 11-50
Founded date: 2019
Investors 5
| Date | Name | Website |
| - | Creative V... | creativeve... |
| - | North Sout... | northsouth... |
| - | Endless Fr... | endlessfro... |
| - | Cloudstone... | cloudstone... |
| - | StartX | startx.com |
Mentions in press and media 5
| Date | Title | Description |
| 14.01.2026 | IMVARIA Secures Strategic Investments for AI-Driven Lung Diagnostics | IMVARIA, a Berkeley health tech innovator, secured strategic funding. New capital expands its AI-driven diagnostic services for lung diseases. InHealth Ventures led the round. Labcorp Venture Fund and Cedar Crest Holdings participated. IMVA... |
| 08.01.2026 | IMVARIA Announces Strategic Investments For AI-Based Digital Biomarker Solutions | IMVARIA, a Berkeley, California-based health tech company developing AI-driven digital biomarker solutions, announced it has secured strategic investments from new and existing investors to accelerate growth and expand its AI-powered diagno... |
| 08.01.2026 | IMVARIA Raises Funding | IMVARIA, a Berkeley, CA-based health tech company, raised an undisclosed amount in funding. The round was led by InHealth Ventures with participation from the Labcorp Venture Fund and existing partner Cedar Crest Holdings. The company inten... |
| 03.11.2023 | IMVARIA and Mayo Clinic Partner to Develop AI Digital Biomarkers for Cancer | IMVARIA Inc., a health tech company pioneering AI-driven digital biomarker solutions announced a collaboration through a know-how agreement with Mayo Clinic to develop AI designed to significantly improve the analysis and understanding of c... |
| 21.05.2023 | IMVARIA Announces Data Demonstrating Company’s Non-Invasive Digital Biomarker for Predicting Mortality in Interstitial Lung Diseases | Data presented at ATS 2023 show IMVARIA’s lead digital biomarker Fibresolve predicts risk of death in ILD IMVARIA, a health tech company pioneering AI-driven digital biomarker solutions, announced data from a study evaluating the company’s ... |